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Abstract
Background: Tobacco use is associated with an increased prevalence of cardiovascular disease. N-terminal pro-brain natiuretic
peptide (NT-proBNP), a widely available biomarker that is associated with cardiovascular outcomes in other conditions, has not
been investigated as a predictor of mortality in tobacco smokers. We hypothesized that NT-proBNP would be an independent
prognostic marker in a cohort of well-characterized tobacco smokers without known cardiovascular disease.
Methods: Clinical data from 796 subjects enrolled in two prospective tobacco exposed cohorts was assessed to determine
factors associated with elevated NT-proBNP and the relationship of these factors and NT-proBNP with mortality.
Results: Subjects were followed for a median of 562 (IQR 252 – 826) days. Characteristics associated with a NT-proBNP
above the median ($49 pg/mL) were increased age, female gender, and decreased body mass index. By time-to-event
analysis, an NT-proBNP above the median ($49 pg/mL) was a significant predictor of mortality (log rank p= 0.02). By
proportional hazard analysis controlling for age, gender, cohort, and severity of airflow obstruction, an elevated NT-proBNP
level ($49 pg/mL) remained an independent predictor of mortality (HR= 2.19, 95% CI 1.07–4.46, p = 0.031).
Conclusions: Elevated NT-proBNP is an independent predictor of mortality in tobacco smokers without known
cardiovascular disease, conferring a 2.2 fold increased risk of death. Future studies should assess the ability of this
biomarker to guide further diagnostic testing and to direct specific cardiovascular risk reduction inventions that may
positively impact quality of life and survival.
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Introduction
Tobacco use is associated with an increased risk of cardiovascular
disease, including both coronary artery disease (CAD) and congestive
heart failure (CHF) [1,2,3,4].Moreover, it has been demonstrated that
independent of the presence of cardiovascular risk factors, patients
with chronic obstructive lung disease (COPD) have double the risk of
acute myocardial infarction and over four and one half times the risk
of CHF compared to matched controls [5]. Cardiovascular disease is
the most common reason for hospital admission in patients with
COPD and is a leading cause of death [6,7,8,9].
Brain natriuretic peptide and its precursor, amino terminal pro-
brain natiuretic peptide (NT-proBNP), are peptides secreted in
response to cardiomyocyte stretch; both have well-characterized
diagnostic and prognostic indicators in several cardiovascular
disorders [10,11,12,13]. Tobacco smokers have increased NT-
proBNP levels compared to non-smokers[14]; in addition, there is
evidence that in smokers with COPD elevated NT-proBNP levels
are associated with decreased physical activity, exercise tolerance,
and latent heart failure [15,16]. However, NT-proBNP has not
been investigated as a predictor of mortality in tobacco smokers
without known cardiovascular disease.
We therefore hypothesized and found that elevated NT-
proBNP levels independently predict increased mortality in a
large cohort of well-characterized tobacco smokers free of
prevalent cardiovascular disease. Our results suggest that NT-
proBNP can serve as a readily available diagnostic and prognostic
screening tool in this at-risk patient population.
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Methods
Ethics Statement
All subjects provided written informed consent and the study
was approved by the University of Pittsburgh Medical Center
Institutional Review Board.
Study Design and Study Population
Subjects were retrospectively analyzed from two large prospec-
tive cohorts, the University of Pittsburgh Medical Center COPD
Patient Registry and the University of Pittsburgh Specialized
Centers in Clinically Oriented Research in COPD cohort and
enrolled between the years of 2003 through 2010. Subjects were
recruited from the university-based outpatient pulmonary clinic
and included a spectrum of obstructive lung disease severity.
Inclusion criteria for enrollment in both cohorts were similar and
required an age $40 years and at least a 10 pack year history of
tobacco use; those with any active pulmonary or systemic
condition, not related to obstructive lung disease, with significant
clinical impact, or significant obesity (body mass index (BMI)
$36 kg/m2), were not enrolled into these cohorts. Exclusion
criteria for this analysis included any history of CAD or CHF. Due
to the renal clearance of NT-proBNP, renal insufficiency was an
additional exclusion criteria (serum creatinine of $2.0 mg/dL)
[17,18].
Clinical Data Collection
Pulmonary function tests were performed at registry enrollment
in accordance with published recommendations [19,20,21]; post-
bronchodilator values were used for all analyses and compared to
standard population-derived equations [22,23]. Dyspnea was
scored using the modified Medical Research Council (mMRC)
scale [24].
Plasma Level of NT-proBNP
Venous blood sample was obtained using Vacutainer tube
(sodium citrate as anti-coagulator, BD, Franklin Lakes NJ, USA) at
registry enrollment. Plasma samples were isolated within 2 hours
of collection from the patient and immediately stored at 280uC.
NT-proBNP level in plasma was analyzed using a commercially
available immunoassay (Roche Elecsys 2010 analyzer, Roche
Diagnostics, Manheim, Germany) according to the manufacturer’s
instruction at the end of the clinical follow up period and after all
mortality data were collected [25,26,27]. Subjects with NT-
proBNP values below the lower detection limit (5 pg/mL) were
assigned a value of 5 pg/mL. Laboratory personnel were blinded
to survival status of the study participants.
Definitions
The exclusion criteria of CAD included any subject reported
medical diagnosis of angina, myocardial infarction, or coronary
revascularization procedure while that of CHF included any
subject reported medical diagnosis of heart failure, irrespective of
whether reported to be left or right-sided heart failure. Death was
ascertained via review of the national Social Security index.
Statistical Analysis
Baseline characteristics and clinical outcomes were examined
via mean6 standard deviation (continuous variables) or as percent
(categorical variables). The cohort distribution of NT-proBNP was
markedly skewed; there were a large number of patients with low
NT-proBNP values and few patients with significantly elevated
NT-proBNP levels. Despite transformation the distribution was
not normal and therefore the raw values of NT-proBNP were
analyzed as a categorical variable dichotomized around the
median. Univariate analysis of variables between groups was
performed via Student’s t tests, Wilcoxon rank-sum tests, or via
chi-square tests, as appropriate. Time of survival was calculated
from date of registry enrollment until death, with censoring at the
date of last query of the Social Security index (March 2010).
Multivariable logistic regression analysis using elevated NT-
proBNP (above the median) as the dependent outcome was
performed to identify relevant predictor variables; variables found
to have a p value #0.20 in univariate analysis were included in a
backward elimination process to arrive at the final model. Survival
was assessed via the Kaplan-Meier method and the log-rank test.
The strength of the association between mortality and elevated
NT-proBNP was assessed via a proportional hazard regression,
adjusting for cohort group, age, gender, and severity of obstructive
lung disease. Logistic regression model discrimination was assessed
via the Hosmer and Lemeshow test. The proportional hazard
assumption was assessed via Schoenfeld residuals. A two-sided p-
value of#0.05 was considered statistically significant. All statistical
analyses were performed with Stata, version 10 (StataCorp LP,
College Station TX).
Results
A total of 796 subjects from the two tobacco exposed cohorts
were included in this analysis. Baseline clinical characteristics are
shown in Table 1. The median length of follow-up was 562 days
(IQR 252–826 days). 7.4% of subjects had a NT-proBNP value
below the lower limit of detection.
Predictors of elevated N-terminal pro-BNP
Correlation analysis between raw NT-proBNP levels and
subject characteristics is shown in Table S1. Clinical character-
istics found to be associated with elevated NT-proBNP (above the
median) in univariate analysis are shown in Table 2. In
multivariable regression modeling incorporating all of those
variables with a p value#0.20, the following variables were found
to independently predict an elevated NT-proBNP: increasing age
(per decade) (OR 2.1, 95% CI 1.7–2.7, p,0.001), female gender
(OR 2.4, 95% CI 1.7–3.4, p,0.001) and decreasing BMI (per kg/
m2) (OR 0.96, 95% CI 0.93–1.0, p = 0.04).
Predictors of Mortality
Overall mortality in the study cohort was 5.3% (n= 42).
Survival at specific time points of follow up is shown in Table S2.
In those patients who died during the study period the median
NT-proBNP level was 71 pg/mL (IQR 36–107 pg/mL), com-
pared to a median value of 47 pg/mL (IQR 21–93 pg/mL) in
those who remained alive at the end of the study period (p = 0.02).
Percent mortality was 7.3% in those with NT-proBNP values
above the median ($49 pg/mL), compared to 3.3% in those with
NT-proBNP levels below the median (p = 0.01). Similar results
were found when NT-proBNP was analyzed by tertiles (Table
S3).By time-to-event (Kaplan-Meier) analysis, an NT-proBNP
above the median ($49 pg/mL) was a significant predictor of
mortality in the entire study cohort (log rank p= 0.02) (Figure 1).
Other predictors of mortality in univariate proportional hazard
analyses are shown in Table 3.
In a multivariable proportional hazards model controlling for
group (either of the tobacco smoking cohorts), age, gender, and
degree of airflow obstruction (FEV1 percent predicted), elevated
NT-proBNP (above the median of49 pg/mL) remained an
independent predictor of mortality (HR=2.19, 95% CI 1.07–
NT-proBNP Predicts Mortality in Tobacco Smokers
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4.46, p = 0.031). A similar trend of increased mortality was found
when repeating the analysis across tertiles of increasing NT-
proBNP (Tables S4 and S5). In this multivariate model, FEV1
percent predicted (per decile, HR=0.75, 95%CI 0.65–0.87,
p,0.001) was also significantly associated with mortality while
cohort group, age, and gender were not associated with mortality.
When other factors known to have prognostic significance in
COPD were assessed in the same proportional hazard model
controlling for group, age, gender, and degree of airflow
obstruction (FEV1 percent predicted), decreasing diffusion capac-
ity (DLCO) (per decile, % predicted HR=0.68, 95% CI 0.50–
0.93, p= 0.015) and hyperinflation (RV/TLC ratio) (per decile, %
HR=1.71, 95% CI 1.10–2.67, p = 0.017) independently predicted
mortality while low BMI (#21 kg/m2) (HR=2.24, 95% CI 0.91–
5.54, p = 0.08), and mMRC dyspnea score (HR=1.26, 95% CI
0.89–1.80, p = 0.19) did not (Figure 2).
Discussion
In this study we have demonstrated that an elevated NT-
proBNP level, independent of the degree of airflow obstruction, is
a significant predictor of mortality in a large tobacco smoking
cohort without known cardiovascular disease. Specifically, a NT-
proBNP value of $49 pg/mL conferred a 2.2 fold increased risk
of death independent of the severity of airflow obstruction and of
other known prognostic indicators.
While NT-proBNP has not previously been reported to be a
prognostic marker in tobacco smokers, elevated NT-proBNP has
been associated with increased mortality in multiple other
conditions, including CAD, CHF, and pulmonary arterial
hypertension [11,12,13,28]. We hypothesize that the increased
mortality observed in our cohort is attributable to latent heart
disease. This supposition is based upon literature that demon-
strates that the increase in mortality associated with elevated NT-
proBNP levels is concordant with an increase in cardiovascular
morbidity and mortality [17,18,29]. However, the lack of
diagnostic cardiac imaging or cause-specific mortality data in
our cohort makes it impossible to substantiate this hypothesis.
Table 1. Baseline Characteristics of the Total Study
Population.
Characteristic Total Population
Demographics
Age*(years) 6468
Gender (% female) 46
BMI (kg/m2) 27.664.9
Pack Years Tobacco* 51628
Disease Characteristics
FEV1* (% predicted) 69628
FVC* (% predicted) 87619
FEV1/FVC ratio* (percent) 58618
FRC* (% predicted) 107631
DLCO* (% predicted) 62624
GOLD Stage (%)
0 (At-risk) 35
I 12
II 26
III–IV 27
Oxygen requirement (%) 21
mMRC Dyspnea Score* 2.361.5
NT-proBNP Distribution(pg/mL)
Mean 6 SD 996262
Median 49
25th percentile 22
75th percentile 94
*mean 6 SD.
Definitions of abbreviations: BMI = body mass index; DLCO=diffusion capacity
for carbon monoxide; FEV1 = forced expiratory volume in one second;
FVC = forced vital capacity; FRC= functional residual capacity; GOLD=Global
Initiative for Chronic Obstructive Lung Disease; mMRC=modified Medical
Research Council; NT-proBNP=N-terminal pro brain natriuretic peptide.
doi:10.1371/journal.pone.0027416.t001
Table 2. Predictors of Elevated N-terminal pro-BNP ($49 pg/mL).
Variable Low NT-proBNP High NT-proBNP P Value
N=796 total*
Demographics
Age{ (years) 6267 6668 ,0.001
Gender (% female) 38 54 ,0.001
BMI (kg/m2) { (n = 676 total) 28.064.7 27.265.1 0.05
Pack years tobacco{ 51631 50626 0.57
Disease Characteristics
FEV1{ (% predicted) 69629 69628 0.84
FVC{ (% predicted) 8618 86619 0.39
FRC{ (% predicted) (n = 575 total) 106634 108628 0.34
DLCO{ (% predicted) (n = 680 total) 64624 61624 0.17
mMRC Dyspnea Score{ 2.261.5 2.361.4 0.21
*for each variable unless otherwise indicated.
{mean 6 SD.
Definitions of abbreviations: BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; FRC= functional residual capacity;
DLCO=diffusion capacity for carbon monoxide; mMRC=modifed Medical Research Council.
doi:10.1371/journal.pone.0027416.t002
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In addition to NT-proBNP, other clinical characteristics known
to predict mortality in tobacco smokers, including age, FEV1
percent predicted, hyperinflation (RV/TLC ratio), mMRC
dyspnea scores, and low BMI (#21 kg/m2), were found to be
associated with mortality in our cohort in univariate analysis
[30,31,32,33,34]. Notably, in multivariable analysis, NT-proBNP,
FEV1, hyperinflation, and DLCO remained independent predic-
tors of mortality. The finding that an elevated NT-proBNP is
associated with mortality in tobacco users with a range of
obstructive lung disease gives credence to the idea that this
biomarker may be useful in assessing risk of death in those without
worrisome traditional prognostic factors [5,7].
The identification of heart disease in tobacco smokers can be
diagnostically challenging as symptoms of cardiovascular disease
and obstructive lung disease overlap [35]. Rutten and colleagues,
in a study of stable COPD patients, found that a NT-proBNP
value of .125 pg/mL was useful in detecting latent heart failure
[15]. We found that 17.3% of our study subjects had a NT-
proBNP value above this threshold. Thus, the results of our work,
which show an increased risk of mortality, complement the
diagnostic properties defined by others of NT-proBNP in this
patient population at risk for cardiovascular disease. We propose
that, in the context of additional studies, NT-proBNP could be
used to risk-stratify tobacco smokers for diagnostic testing or
therapeutic interventions, such as the prescription of beta blockers,
which have recently been shown to reduce mortality in COPD
patients both with and without cardiovascular disease [36,37,38].
The median value of NT-proBNP we found in our subjects
(49 pg/mL) with a wide spectrum of obstructive lung disease and
without known cardiovascular disease is not unexpected in
comparison to other study groups. For example, in a healthy
community dwelling cohort of adults .60 years old, the median
NT-proBNP value for men was 40 pg/mL and was 78 pg/mL for
women.[39] In our study cohort, the gender specific median NT-
proBNP values are 40 pg/mL for men and 58 pg/mL for women.
Watz et al. report a median NT-proBNP value of 67 pg/mL in
their investigation of COPD patients without active heart disease,
although the degree of airflow obstruction was greater in their
study than ours (56% versus 69% percent predicted FEV1,
respectively) [16]. Likewise, in accordance with the literature, we
found in our study that increasing age, female gender, and
decreasing BMI were independently associated with an elevated
NT-proBNP [29,40,41,42]. As reported by others, we found no
correlation between severity of airflow obstruction as assessed by
FEV1 and NT-proBNP levels [15,16].
Although our study was based on a large prospective cohort of
smokers with a wide spectrum of airflow obstruction and displayed
good external validity in terms of corroborating well-described
predictors of both elevated NT-proBNP and of mortality, there are
certainly limitations worthy of consideration. We do not have
detailed information regarding the presence of comorbid condi-
tions in our subjects. In addition, we are unable to characterize the
nature and severity of cardiovascular disease in our study patients.
Finally, we lack information on exercise testing, which limits our
ability to compare NT-proBNP to this important predictor of
mortality either in isolation or in the form of the validated BODE
(body mass index, airway obstruction, dyspnea, and exercise
capacity) index [32].
Table 3. Clinical Variables and Mortality in Univariate Proportional Hazard Survival Analysis.
Hazard Ratio 95% Confidence Interval P Value
Demographics
Age (per decade) 1.46 1.01 – 2.19 0.046
Gender (male) 1.51 0.77 – 2.97 0.23
BMI (kg/m2) 0.96 0.90 – 1.02 0.18
Low BMI (#21 kg/m2) 3.56 1.55–8.17 0.003
Pack Years tobacco (per year) 1.00 0.99 – 1.01 0.53
Laboratory
Dichotomized NT-proBNP ($49 pg/mL) 2.17 1.13 – 4.18 0.02
Disease Characteristics
FEV1 (per decile, % predicted) 0.75 0.65 – 0.85 ,0.001
FRC (per decile, % predicted) 1.19 1.10 – 1.29 ,0.001
RV/TLC ratio (per decile, %) 1.95 1.38 – 2.76 ,0.001
DLCO (per decile, % predicted) 0.57 0.45 – 0.73 ,0.001
mMRC Score (per point) 1.71 1.28 – 2.27 ,0.001
Definitions of abbreviations:BMI =body mass index; DLCO=diffusion capacity for carbon monoxide; FEV1 = forced expiratory volume in 1 second; FRC = functional
residual capacity; mMRC=modified Medical Research Council; NT-proBNP=N-terminal pro brain natriuretic peptide; RV/TLC ratio = residual volume to total lung
capacity ratio.
doi:10.1371/journal.pone.0027416.t003
Figure 1. Univariate Survival Analysis. Kaplan-Meier survival curve
of those with High ($49 pg/mL) (solid line) versus Low (,49 pg/mL)
(dashed line) NT-proBNP levels. Log-rank test = 0.02. NT-proBNP=N-
terminal pro-brain natriuretic peptide.
doi:10.1371/journal.pone.0027416.g001
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In conclusion, we have shown in a tobacco smoking cohort
without known cardiovascular disease that an elevated NT-
proBNP is associated with increased mortality independent of
airflow obstruction. The combined diagnostic and prognostic
capabilities of NT-proBNP suggest that this readily available
biomarker could be used to risk stratify those with or at-risk for
COPD, a population with an increased prevalence of heart
disease. Our findings should be confirmed in other cohorts of
tobacco exposed patients and compared to established models of
mortality risk assessment, such as the BODE index. If NT-proBNP
is found to be a validated predictor of mortality, future prospective
studies should assess the role of NT-proBNP to influence further
diagnostic testing and to direct specific cardiovascular risk
reduction inventions, such as beta blockade therapy, to impact
quality of life and survival.
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